Orencia (abatacept) — United Healthcare
moderately to severely active rheumatoid arthritis
Initial criteria
- Diagnosis of moderately to severely active rheumatoid arthritis
- Patient is not receiving Orencia in combination with another targeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept), Olumiant (baricitinib), Simponi (golimumab), Rinvoq (upadacitinib), Xeljanz (tofacitinib)]
Reauthorization criteria
- Documentation of positive clinical response to Orencia therapy
- Patient is not receiving Orencia in combination with another targeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept), Olumiant (baricitinib), Simponi (golimumab), Rinvoq (upadacitinib), Xeljanz (tofacitinib)]
Approval duration
12 months